101.51
+0.87(+0.86%)
Currency In USD
| Previous Close | 100.64 |
| Open | 100.83 |
| Day High | 103.07 |
| Day Low | 100.57 |
| 52-Week High | 106.52 |
| 52-Week Low | 45.91 |
| Volume | 325,236 |
| Average Volume | 731,880 |
| Market Cap | 6.74B |
| PE | -33.17 |
| EPS | -3.06 |
| Moving Average 50 Days | 95.93 |
| Moving Average 200 Days | 69.03 |
| Change | 0.87 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $4,131.46 as of September 30, 2025 at a share price of $101.51. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $4,684.36 as of September 30, 2025 at a share price of $101.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
GlobeNewswire Inc.
Aug 20, 2025 8:01 PM GMT
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
GlobeNewswire Inc.
Jul 22, 2025 8:01 PM GMT
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
GlobeNewswire Inc.
Jul 12, 2025 10:00 PM GMT
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of